Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
SNTI
SNTI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest SNTI ETF News Today | Earnings, Events & Price Alerts
SNTI News
Senti Bio to Present at Global Healthcare Conference
1d ago
Newsfilter
Senti Bio Participates in Cell & Gene Live Event on Innovative Therapies
Feb 20 2026
Newsfilter
Senti Bio's SENTI-202 Clinical Data Shows Promising Results
Feb 11 2026
Newsfilter
Senti Biosciences Grants New Employee 13,680 Stock Options at $1.31 Each
Dec 18 2025
Globenewswire
Senti Biosciences Grants New Employee 13,680 Stock Options at $1.31 Each
Dec 18 2025
Newsfilter
Post-Market Surge: Stoke Therapeutics, Alpha Tau Medical, and Compass Pathways Top Biotech Gainers
Dec 10 2025
NASDAQ.COM
What’s Causing the Decline in Senti Bio Stock Focused on Gene Therapy Today?
Dec 09 2025
Benzinga
Senti Biosciences Obtains FDA RMAT Designation for SENTI-202
Dec 09 2025
NASDAQ.COM
Senti Bio Receives FDA RMAT Designation for SENTI-202, Demonstrating Significant Efficacy
Dec 09 2025
Newsfilter
Senti Bio Reports 50% Efficacy for SENTI-202 in R/R AML Patients
Dec 09 2025
Newsfilter
Senti Reports Encouraging Phase 1 Results for SENTI-202 in Relapsed/Refractory AML
Dec 09 2025
NASDAQ.COM
Repare Surges 30%, Nuvalent Rises 9% in After-Hours Biotech Gains
Nov 17 2025
NASDAQ.COM
Senti Bio to Showcase at Chardan's 9th Annual Genetic Medicines Conference
Oct 16 2025
Newsfilter
Senti Bio to Showcase at the MedInvest Biotech & Pharma Conference
Sep 18 2025
Newsfilter
Senti Bio to Showcase at the 27th Annual Global Investment Conference Hosted by H.C. Wainwright
Sep 02 2025
Newsfilter
Senti Bio Participates in Virtual Investor "What This Means" Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia
Aug 12 2025
Newsfilter
Show More News
